These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
568 related items for PubMed ID: 18474441
21. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, Chuang SE. Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241 [Abstract] [Full Text] [Related]
22. PPARgamma ligands suppress the feedback loop between E2F2 and cyclin-E1. Komatsu Y, Ito I, Wayama M, Fujimura A, Akaogi K, Machida H, Nakajima Y, Kuroda T, Ohmori K, Murayama A, Kimura K, Yanagisawa J. Biochem Biophys Res Commun; 2008 May 23; 370(1):145-8. PubMed ID: 18355447 [Abstract] [Full Text] [Related]
23. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG. J Cell Biochem; 2005 Nov 01; 96(4):760-74. PubMed ID: 16149072 [Abstract] [Full Text] [Related]
24. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Shim J, Kim BH, Kim YI, Kim KY, Hwangbo Y, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R. Int J Oncol; 2010 Jan 01; 36(1):223-31. PubMed ID: 19956851 [Abstract] [Full Text] [Related]
25. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W, Toge T. Anticancer Res; 2003 Jan 01; 23(1A):267-73. PubMed ID: 12680223 [Abstract] [Full Text] [Related]
26. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Eucker J, Sterz J, Krebbel H, Zavrski I, Kaiser M, Zang C, Heider U, Jakob C, Elstner E, Sezer O. Anticancer Drugs; 2006 Aug 01; 17(7):763-9. PubMed ID: 16926626 [Abstract] [Full Text] [Related]
27. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K. Cancer Detect Prev; 2008 Aug 01; 32(3):259-66. PubMed ID: 18789607 [Abstract] [Full Text] [Related]
28. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, Chapleur Y, Flament S. Breast Cancer Res Treat; 2010 Nov 01; 124(1):101-10. PubMed ID: 20054646 [Abstract] [Full Text] [Related]
29. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Han C, Demetris AJ, Michalopoulos GK, Zhan Q, Shelhamer JH, Wu T. Hepatology; 2003 Jul 01; 38(1):167-77. PubMed ID: 12829999 [Abstract] [Full Text] [Related]
31. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Yoshimura R, Matsuyama M, Hase T, Tsuchida K, Kuratsukuri K, Kawahito Y, Sano H, Segawa Y, Nakatani T. Int J Mol Med; 2003 Dec 01; 12(6):861-5. PubMed ID: 14612958 [Abstract] [Full Text] [Related]
33. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I. Breast Cancer Res Treat; 2008 Dec 01; 112(3):437-51. PubMed ID: 18204896 [Abstract] [Full Text] [Related]
34. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Takashima T, Fujiwara Y, Hamaguchi M, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Higuchi K, Arakawa T. Oncol Rep; 2005 Apr 01; 13(4):601-6. PubMed ID: 15756430 [Abstract] [Full Text] [Related]
35. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Lovekamp-Swan T, Chaffin CL. Mol Cell Endocrinol; 2005 Apr 15; 233(1-2):15-24. PubMed ID: 15767042 [Abstract] [Full Text] [Related]
36. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand. Nonaka M, Tazuma S, Hyogo H, Kanno K, Chayama K. J Gastroenterol Hepatol; 2008 Jul 15; 23(7 Pt 2):e198-206. PubMed ID: 17868335 [Abstract] [Full Text] [Related]
37. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Wali VB, Bachawal SV, Sylvester PW. Exp Biol Med (Maywood); 2009 Jun 15; 234(6):639-50. PubMed ID: 19359655 [Abstract] [Full Text] [Related]
38. Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Hseu YC, Chen SC, Chen HC, Liao JW, Yang HL. Food Chem Toxicol; 2008 Aug 15; 46(8):2680-8. PubMed ID: 18550246 [Abstract] [Full Text] [Related]
39. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Bae MA, Rhee H, Song BJ. Toxicol Lett; 2003 Mar 20; 139(1):67-75. PubMed ID: 12595159 [Abstract] [Full Text] [Related]
40. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells. Zhu H, Pan X, Qi H, Wang X, Hou S, Han B, Liu Z, Xu L. Oncol Rep; 2011 Jan 20; 25(1):81-90. PubMed ID: 21109961 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]